- Home
- STTK vs SCPH Comparison
STTK vs SCPH Comparison
Compare STTK & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SCPH
- Stock Information
- Founded
- STTK 2016
- SCPH 2013
- Country
- STTK United States
- SCPH United States
- Employees
- STTK N/A
- SCPH N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- SCPH Health Care
- Exchange
- STTK Nasdaq
- SCPH Nasdaq
- Market Cap
- STTK 56.8M
- SCPH 179.6M
- IPO Year
- STTK 2020
- SCPH 2017
- Fundamental
- Price
- STTK $1.22
- SCPH $3.49
- Analyst Decision
- STTK Hold
- SCPH Strong Buy
- Analyst Count
- STTK 3
- SCPH 2
- Target Price
- STTK $2.00
- SCPH $15.00
- AVG Volume (30 Days)
- STTK 182.2K
- SCPH 442.5K
- Earning Date
- STTK 02-27-2025
- SCPH 11-13-2024
- Dividend Yield
- STTK N/A
- SCPH N/A
- EPS Growth
- STTK N/A
- SCPH N/A
- EPS
- STTK N/A
- SCPH N/A
- Revenue
- STTK $6,435,000.00
- SCPH $30,278,000.00
- Revenue This Year
- STTK $313.04
- SCPH $172.64
- Revenue Next Year
- STTK N/A
- SCPH $131.43
- P/E Ratio
- STTK N/A
- SCPH N/A
- Revenue Growth
- STTK 382.75
- SCPH 303.87
- 52 Week Low
- STTK $0.94
- SCPH $3.08
- 52 Week High
- STTK $11.76
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- SCPH 44.62
- Support Level
- STTK $1.13
- SCPH $3.27
- Resistance Level
- STTK $1.39
- SCPH $3.58
- Average True Range (ATR)
- STTK 0.11
- SCPH 0.19
- MACD
- STTK 0.00
- SCPH 0.01
- Stochastic Oscillator
- STTK 18.18
- SCPH 22.92
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.